At Dreavent, our investment strategy is meticulously designed to maximize returns while minimizing risks.
STRATEGY
By focusing on transformative therapeutic developments, leveraging our deep industry knowledge, and utilizing our extensive network, we ensure our investments have the highest potential for success. Our approach is built on several foundational principles that guide our investment decisions and ensure we remain at the forefront of the biotech industry.
Risk Mitigation Strategy
At Dreavent, our mission is to advance research in untreatable diseases and develop new treatments to improve patient health.
We prioritize investments in biotech companies that align with our Risk Mitigation Strategy. This includes partnering with large funds and pharmaceutical companies to reduce financial and scientific risks, investing in companies with proven safety records in animal testing, and focusing on products in advanced stages of development.
Our approach emphasizes the use of established methods and strong intellectual property to safeguard our investments. By collaborating with reputable partners for successful exits, we aim to achieve sustainable returns and make a significant impact on health care.
BASIC SCIENCE RISK
Many biotech companies fail when transitioning from in vitro cellular studies to in vivo animal studies, from small to large animal testing, or considering broader requirements of metabolism or safety.
We invest in companies that are backed by at least one large pharma, and are at or ready to start, human clinical stage trials.
TECHNOLOGY RISK
Some biotech companies are developing novel interventions that face challenges such as manufacturing, costs, or regulatory issues.
We focus on companies with established modalities with a track record in pharmaceutical R&D.
SAFETY RISK
Biotech companies often encounter safety concerns in later animal toxicology studies.
We invest in companies that have passed these critical safety studies and received FDA approval to proceed with human studies.
Many biotech companies face the risk of running out of capital despite making good progress.
FINANCING RISK
We invest in companies with strong venture capital syndicates capable of providing continued financial support.
COMMERCIAL RISK
Biotech companies may target niche markets with limited commercial potential.
We only invest in companies with large pharma partners or investors who validate the commercial viability of their products.
Dreavent’s Engine - Proactive Seeking vs. Traditional Passive Approach
Our Commitment to Excellence
Dreavent is committed to delivering exceptional value to our investors by leveraging these market conditions and our strategic approach. Our focus on de-risked investments, rigorous selection processes, strategic partnerships, and targeted therapeutic areas positions us to capitalize effectively on current market dynamics. By ensuring that our investments are well-supported, innovative, and have the potential for significant returns, we maintain our dedication to excellence and our mission to improve human health.
Selection Criteria
Our focus on strong industry partnerships, established venture capital support, later stages of development, and commercially precedented therapeutic modalities allows us to effectively mitigate risks and maximize returns.
Investment Strategy
Dreavent's investment strategy zeroes in on life science companies at crucial development stages, prioritizing those that have made significant headway from IND submission to Phase 2 clinical trials.
Fund Selection Process
Our twice-yearly rigorous selection process ensures high-quality biotech investments. We prioritize companies backed by top VCs and pharma firms, focusing on Oncology, Neuroscience, Immunology, and Cardiovascular diseases.